Why Ocugen Shares Are Falling

Ocugen Inc OCGN shares are trading lower by 19.6% at $3.40 Wednesday morning after the company announced pricing of a $53.5 million public offering of common stock.

Ocugen shares were otherwise rising during Tuesday's trading session after company announced the FDA lifted its clinical hold on the company's COVID-19 vaccine study in the US.

See Also: 'I'm Waiting To Catch Somebody Else's Falling Knife': Why Josh Brown Placed Limit Orders To Buy These 4 Stocks

Ocugen is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases.

Ocugen has a 52-week high of $17.65 and a 52-week low of $2.87.